The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer
van Elmpt, Wouter × De Ruysscher, Dirk van der Salm, Anke Lakeman, Annemarie van der Stoep, Judith Emans, Daisy Damen, Eugène Ollers, Michel Sonke, Jan-Jakob Belderbos, José #
Elsevier Science Publishers
Radiotherapy and Oncology vol:104 issue:1 pages:67-71
The local site of relapse in non-small cell lung cancer (NSCLC) is primarily located in the high FDG uptake region of the primary tumour prior to treatment. A phase II PET-boost trial (NCT01024829) randomises patients between dose-escalation of the entire primary tumour (arm A) or to the high FDG uptake region inside the primary tumour (>50% SUV(max)) (arm B), whilst giving 66Gy in 24 fractions to involved lymph nodes. We analysed the planning results of the first 20 patients for which both arms A and B were planned.